MicroPort CardioFlow Medtech Corporation (MP CARDIOFLOW-B, 02160) reported a reduction in its authorized and issued share capital following a share consolidation that became effective on February 24, 2026. The total authorized capital remains USD 50,000, while the number of authorized shares shifted from 10.00 billion Ordinary Shares to 2.00 billion Ordinary Shares. The par value was adjusted from USD 0.000005 to USD 0.000025 per share.

The share consolidation reduced the total issued shares from 6.37 billion to 1.27 billion, reflecting a net decrease of 5.09 billion Ordinary Shares. The public float requirement remained in compliance as of February 28, 2026. The exercise prices under the company's share option schemes were adjusted from USD 0.16 to USD 0.80, HKD 1.002 to HKD 5.01, and HKD 13.72 to HKD 68.60 following the effective date of the share consolidation.

No new shares were issued pursuant to share options, and no treasury shares were involved during February 2026. The cancellation of certain share options and the adjusted share numbers under the schemes reflect the effects of the share consolidation. The company confirmed that all procedures related to the issuance, consolidation, and compliance requirements have been fulfilled, with no further changes in treasury shares or Hong Kong Depositary Receipts.